ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Gross of the placeholder expense ratio and trading costs · not investor results
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1LLY | ELI LILLY & CO | Healthcare | $1.34T | 51.60% |
2AMGN | AMGEN INC | Healthcare | $252.64B | 9.71% |
3VRTX | VERTEX PHARMACEUTICALS INC | Healthcare | $137.57B | 5.29% |
4BMY | BRISTOL MYERS SQUIBB CO | Healthcare | $127.39B | 4.90% |
5COR | CENCORA INC | Healthcare | $66.67B | 2.56% |
6IDXX | IDEXX LABORATORIES INC | Healthcare | $54.99B | 2.11% |
7A | AGILENT TECHNOLOGIES INC | Healthcare | $48.78B | 1.87% |
8IQV | IQVIA HOLDINGS INC | Healthcare | $44.68B | 1.72% |
9MTD | METTLER TOLEDO INTERNATIONAL INC | Healthcare | $34.43B | 1.32% |
10ZTS | ZOETIS INC | Healthcare | $33.71B | 1.30% |
11RMD | RESMED INC | Healthcare | $33.60B | 1.29% |
12ILMN | ILLUMINA INC | Healthcare | $31.68B | 1.22% |
13DXCM | DEXCOM INC | Healthcare | $30.35B | 1.17% |
14WST | WEST PHARMACEUTICAL SERVICES INC | Healthcare | $28.65B | 1.10% |
15THC | TENET HEALTHCARE CORP | Healthcare | $22.83B | 0.88% |
16ALNY | ALNYLAM PHARMACEUTICALS INC | Healthcare | $20.98B | 0.81% |
17GH | GUARDANT HEALTH INC | Healthcare | $20.95B | 0.81% |
18MEDP | MEDPACE HOLDINGS INC | Healthcare | $18.37B | 0.71% |
19EXEL | EXELIXIS INC | Healthcare | $17.04B | 0.65% |
20BBIO | BRIDGEBIO PHARMA INC | Healthcare | $15.23B | 0.59% |
21BTSG | BRIGHTSPRING HEALTH SERVICES INC | Healthcare | $14.22B | 0.55% |
22EHC | ENCOMPASS HEALTH CORP | Healthcare | $13.82B | 0.53% |
23HALO | HALOZYME THERAPEUTICS INC | Healthcare | $11.48B | 0.44% |
24PODD | INSULET CORP | Healthcare | $10.36B | 0.40% |
25OSCR | OSCAR HEALTH INC | Healthcare | $9.92B | 0.38% |
26HNGE | HINGE HEALTH INC | Healthcare | $9.83B | 0.38% |
27PTGX | PROTAGONIST THERAPEUTICS INC | Healthcare | $8.77B | 0.34% |
28CORT | CORCEPT THERAPEUTICS INC | Healthcare | $8.07B | 0.31% |
29CYTK | CYTOKINETICS INC | Healthcare | $7.82B | 0.30% |
30PACS | PACS GROUP INC | Healthcare | $7.62B | 0.29% |
31AMRX | AMNEAL PHARMACEUTICALS INC | Healthcare | $7.56B | 0.29% |
32CHE | CHEMED CORP | Healthcare | $7.16B | 0.28% |
33LNTH | LANTHEUS HOLDINGS INC | Healthcare | $6.62B | 0.25% |
34IBRX | IMMUNITYBIO INC | Healthcare | $6.46B | 0.25% |
35CON | CONCENTRA GROUP HOLDINGS PARENT INC | Healthcare | $5.44B | 0.21% |
36PTCT | PTC THERAPEUTICS INC | Healthcare | $5.29B | 0.20% |
37EWTX | EDGEWISE THERAPEUTICS INC | Healthcare | $5.02B | 0.19% |
38SHC | SOTERA HEALTH CO | Healthcare | $4.66B | 0.18% |
39CDNA | CAREDX INC | Healthcare | $4.19B | 0.16% |
40NVST | ENVISTA HOLDINGS CORP | Healthcare | $3.95B | 0.15% |
41OGN | ORGANON & CO | Healthcare | $3.65B | 0.14% |
42TMDX | TRANSMEDICS GROUP INC | Healthcare | $3.20B | 0.12% |
43ACAD | ACADIA PHARMACEUTICALS INC | Healthcare | $3.14B | 0.12% |
44GRDN | GUARDIAN PHARMACY SERVICES INC | Healthcare | $3.13B | 0.12% |
45BHC | BAUSCH HEALTH COMPANIES INC | Healthcare | $3.09B | 0.12% |
46ADMA | ADMA BIOLOGICS INC | Healthcare | $2.94B | 0.11% |
47PGNY | PROGYNY INC | Healthcare | $2.69B | 0.10% |
48AVAH | AVEANNA HEALTHCARE HOLDINGS INC | Healthcare | $2.67B | 0.10% |
49AUPH | AURINIA PHARMACEUTICALS INC | Healthcare | $2.17B | 0.08% |
50BKD | BROOKDALE SENIOR LIVING INC | Healthcare | $2.14B | 0.08% |
51BCRX | BIOCRYST PHARMACEUTICALS INC | Healthcare | $1.98B | 0.08% |
52ZYME | ZYMEWORKS INC | Healthcare | $1.83B | 0.07% |
53ETON | ETON PHARMACEUTICALS INC | Healthcare | $1.77B | 0.07% |
54NRIX | NURIX THERAPEUTICS INC | Healthcare | $1.70B | 0.07% |
55HCSG | HEALTHCARE SERVICES GROUP INC | Healthcare | $1.69B | 0.06% |
56RARE | ULTRAGENYX PHARMACEUTICAL INC | Healthcare | $1.66B | 0.06% |
57ANIP | ANI PHARMACEUTICALS INC | Healthcare | $1.62B | 0.06% |
58NVAX | NOVAVAX INC | Healthcare | $1.45B | 0.06% |
59PAHC | PHIBRO ANIMAL HEALTH CORP | Healthcare | $1.44B | 0.06% |
60ANAB | ANAPTYSBIO INC | Healthcare | $1.43B | 0.05% |
61URGN | UROGEN PHARMA LTD | Healthcare | $1.29B | 0.05% |
62INBX | INHIBRX BIOSCIENCES INC | Healthcare | $1.29B | 0.05% |
63NUTX | NUTEX HEALTH INC | Healthcare | $1.18B | 0.05% |
64FRNM | FREENOME INC | Healthcare | $1.14B | 0.04% |
65ATEC | ALPHATEC HOLDINGS INC | Healthcare | $1.10B | 0.04% |
66IRMD | IRADIMED CORP | Healthcare | $1.09B | 0.04% |
67BVS | BIOVENTUS INC | Healthcare | $915M | 0.04% |
68RIGL | RIGEL PHARMACEUTICALS INC | Healthcare | $860M | 0.03% |
69MGTX | MEIRAGTX HOLDINGS PLC | Healthcare | $844M | 0.03% |
70ZVRA | ZEVRA THERAPEUTICS INC | Healthcare | $664M | 0.03% |
71SRZN | SURROZEN INC | Healthcare | $604M | 0.02% |
72NRC | NRC HEALTH | Healthcare | $565M | 0.02% |
73RCEL | AVITA MEDICAL INC | Healthcare | $509M | 0.02% |
74PHAT | PHATHOM PHARMACEUTICALS INC | Healthcare | $506M | 0.02% |
75EOLS | EVOLUS INC | Healthcare | $475M | 0.02% |
76CTEV | CLARITEV CORP | Healthcare | $459M | 0.02% |
77QTTB | Q32 BIO INC | Healthcare | $264M | 0.01% |
78LFCR | LIFECORE BIOMEDICAL INC | Healthcare | $243M | 0.01% |
79PDEX | PRO DEX INC | Healthcare | $216M | 0.01% |
80ELMD | ELECTROMED INC | Healthcare | $204M | 0.01% |
81RNAC | CARTESIAN THERAPEUTICS INC | Healthcare | $194M | 0.01% |
82STRO | SUTRO BIOPHARMA INC | Healthcare | $159M | 0.01% |
83RLYB | RALLYBIO CORP | Healthcare | $84M | 0.00% |
84ATRA | ATARA BIOTHERAPEUTICS INC | Healthcare | $81M | 0.00% |
85GOSS | GOSSAMER BIO INC | Healthcare | $69M | 0.00% |
86COCH | ENVOY MEDICAL INC | Healthcare | $53M | 0.00% |
Full long-leg book as of November 2026 · cap-weighted · total market cap $2.60T. Hypothetical model holdings — not a registered fund’s portfolio.
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 465-name universe at November 2026. Rows: Large ≥ $4.2B, Small < $1.1B. Columns: Value ≥ 0.67, Growth < 0.36 B/M. The dot marks the capital-weighted centroid of the book — 99% toward Large, 80% toward Growth. +3% unclassified (25 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → November 2026; the right-hand end is the same value as the box’s dot. 86 names now. Hypothetical holdings — descriptive, not P&L.
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
No more than 25% of total assets may be invested in the securities of any one issuer.
At least 50% of total assets must sit in cash, government securities, other RICs, and other securities limited to 5% of assets and 10% of the issuer's voting securities per issuer.
Arithmetically entailed by '40 Act 5(b)(1) diversification (75%/5% asset leg) — it cannot fail independently, so it is reported outside the tally rather than counted as a separate check.
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20261113T032607 rows=2198308 asof=202611 issuers=20261113T043645 rates=20261113T043645
Measured on the 2026-11 formation date across 86 holdings (cap-weighted). A different formation date can produce different verdicts.
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 335 monthly observations · about 3.4 in the 99% tail · paired percentile bootstrap over months
The estimators agree, which is mild evidence the number isn’t an artefact of one method.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Did the edge survive the paper coming out?
There is no “before” to compare against — the predictor was already public when our data begins, so every month shown is out-of-sample relative to the original study.
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 23.2% | 5.4% |
| 3 yearsp.a. | 15.4% | -13.2% |
| 5 yearsp.a. | 10.5% | -7.0% |
| 10 yearsp.a. | 12.7% | -3.7% |
| Since inceptionp.a. | 8.3% | -6.9% |
| Year | Long leg | Long-short |
|---|---|---|
| 202611 mo | 24.4% | 0.5% |
| 2025 | 14.7% | -24.2% |
| 2024 | 4.3% | -5.8% |
| 2023 | 4.1% | -6.8% |
| 2022 | -1.5% | -1.2% |
| 2021 | 25.7% | 18.6% |
| 2020 | 13.6% | -7.2% |
| 2019 | 16.1% | -20.4% |
| 2018 | 4.4% | 21.8% |
| 2017 | 23.6% | -5.8% |
| 2016 | -0.9% | 5.5% |
| 2015 | 4.9% | -7.3% |
| 2014 | 24.1% | -13.3% |
| 2013 | 41.6% | -10.1% |
| 2012 | 17.9% | -25.8% |
| 2011 | 9.5% | 16.1% |
| 2010 | 3.1% | -6.6% |
| 2009 | 18.5% | -2.8% |
| 2008 | -21.9% | 6.1% |
| 2007 | 6.7% | 10.4% |
| 2006 | 6.0% | 1.8% |
| 2005 | 5.6% | 16.6% |
| 2004 | 5.1% | 10.8% |
| 2003 | 12.2% | -33.9% |
| 2002 | -19.7% | 39.3% |
| 2001 | -13.1% | 6.5% |
| 2000 | 33.1% | -74.5% |
| 1999 | -4.3% | -11.9% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through November 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
The Foundry Healthcare Return on Equity Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a Return on Equity signal and holds the top quintile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.